Loading the comparison…
Loading the comparison…
Any covered state and procedure, side by side
| Superficial venous ablation · New Jersey | Superficial venous ablation · New York | |
|---|---|---|
| Surgeons, 2024 | 70 | 132 |
| Medicare fee-for-service cases | 4,906 | 8,630 |
| Growth since 2019 (Medicare FFS) | −2.3%/yr | −5.2%/yr |
| Forecast cases (Medicare FFS) | 6,260 in 2030 | 9,880 in 2030 |
| Forecast growth | +4.1%/yr to 2030 | +2.3%/yr to 2030 |
| Per 1,000 Medicare beneficiaries | 4.5 | 4.5 |
| Medicare Advantage share | 45% | 57% |
| Out of hospital | 97% (−1 pts since 2019) | 97% (−0 pts since 2019) |
| Cases per surgeon | 70 | 65 |
| Top 10 surgeons' share | 46% | 25% |
| Surgeons growing | 10 | 19 |
| New since the base year | 20 | 43 |
| Likely to stop billing it | 18 by 2026 | 23 by 2026 |
| Forecast miss, 1 year (procedure) | 5% | 5% |
| Company payments per surgeon | $738 | $578 |
The counts above are the surgeons MedaRep names: who is growing, who is new, who is likely to stop and which companies engage them.